Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL)
Authors
Armand, P.Zinzani, P. L. L.
Lee, H. J.
Johnson, N.
Brice, P.
Radford, John A
Ribrag, V.
Molin, D.
Vassilakopoulos, T. P.
Tomita, A.
von Tresckow, B.
Shipp, M. A.
Herrera, A. F.
Lin, J. X.
Kim, E.
Chakraborty, S.
Marinello, P.
Moskowitz, C. H.
Affiliation
Dana-Farber Cancer Institute, Boston, MAIssue Date
2021
Metadata
Show full item recordCitation
Armand P, Zinzani PLL, Lee HJ, Johnson N, Brice P, Radford J, et al. Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398805094.Journal
BloodDOI
10.1182/blood-2021-147881Additional Links
https://dx.doi.org/10.1182/blood-2021-147881Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-147881